Work

Supplementary Figures S1 - S6 from Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure S1 - Validation of CCNE1 and CDK2 siRNA-mediated knockdown Supplementary Figure S2 - Validation of CDK2 knockdown mediated by shRNA in vitro and in vivo Supplementary Figure S3 - FACS plots validating incorporation and induction of shRNA into OVCAR3 and CAOV3 cells Supplementary Figure S4 - Characterisation of CDK resistant lines and supplementary data supporting drug treatment Supplementary Figure S5 - Extended Oncoprint figure from TCGA Supplementary Figure S6 - Validation of FT282 over-expression constructs

DOI: 10.1158/1078-0432.22463456.v1

Authors: George Au-Yeung, Franziska Lang, Walid J. Azar, Chris Mitchell, Kate E. Jarman, Kurt Lackovic, Diar Aziz, Carleen Cullinane, Richard B. Pearson, Linda Mileshkin, Danny Rischin, Alison M. Karst, Ronny Drapkin, Dariush Etemadmoghadam, David D.L. Bowtell

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361921214

Cites:

Cited by:

Related to: 10